200,000+ products from a single source!
sales@angenechem.com
Home > Imidazoles > 72559-06-9
72559-06-9 | Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione,16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-,[9S-(9R*,12E,14R*,15S*,16R*,17S*,18S*,19S*,20R*,21R*,22E,24Z)]-
CAS No: 72559-06-9 Catalog No: AG00ICA2 MDL No:MFCD00866816
Product Description
Catalog Number:
AG00ICA2
Chemical Name:
Spiro[9,4-(epoxypentadeca[1,11,13]trienimino)-2H-furo[2',3':7,8]naphth[1,2-d]imidazole-2,4'-piperidine]-5,10,26(3H,9H)-trione,16-(acetyloxy)-6,18,20-trihydroxy-14-methoxy-7,9,15,17,19,21,25-heptamethyl-1'-(2-methylpropyl)-,[9S-(9R*,12E,14R*,15S*,16R*,17S*,18S*,19S*,20R*,21R*,22E,24Z)]-
CAS Number:
72559-06-9
Molecular Formula:
C46H62N4O11
Molecular Weight:
847.0047
MDL Number:
MFCD00866816
IUPAC Name:
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,32-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-1'-(2-methylpropyl)-6,23-dioxospiro[8,33-dioxa-24,27,29-triazapentacyclo[23.6.1.14,7.05,31.026,30]tritriaconta-1(32),2,4,9,19,21,24,26,30-nonaene-28,4'-piperidine]-13-yl] acetate
InChI:
InChI=1S/C46H62N4O11/c1-22(2)21-50-18-16-46(17-19-50)48-34-31-32-39(54)28(8)42-33(31)43(56)45(10,61-42)59-20-15-30(58-11)25(5)41(60-29(9)51)27(7)38(53)26(6)37(52)23(3)13-12-14-24(4)44(57)47-36(40(32)55)35(34)49-46/h12-15,20,22-23,25-27,30,37-38,41,48,52-55H,16-19,21H2,1-11H3/b13-12+,20-15+,24-14-,47-36?/t23-,25+,26+,27+,30-,37-,38+,41+,45-/m0/s1
InChI Key:
ZWBTYMGEBZUQTK-PVLSIAFMSA-N
SMILES:
CO[C@H]1C=CO[C@@]2(C)Oc3c(C2=O)c2C4=NC5(NC4=C(C(=O)c2c(c3C)O)NC(=O)C(=CC=C[C@@H]([C@@H]([C@H]([C@H]([C@H]([C@@H]([C@@H]1C)OC(=O)C)C)O)C)O)C)C)CCN(CC5)CC(C)C
EC Number:
615-780-3
Properties
Complexity:
2110
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
9
Defined Bond Stereocenter Count:
3
Exact Mass:
846.442g/mol
Formal Charge:
0
Heavy Atom Count:
61
Hydrogen Bond Acceptor Count:
14
Hydrogen Bond Donor Count:
5
Isotope Atom Count:
0
Molecular Weight:
847.019g/mol
Monoisotopic Mass:
846.442g/mol
Rotatable Bond Count:
5
Topological Polar Surface Area:
209A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.7
Literature
| Title | Journal |
|---|---|
| The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. | American journal of respiratory and critical care medicine 20120915 |
| Efficacy of rifabutin-loaded microspheres for treatment of Mycobacterium avium-infected macrophages and mice. | Drug delivery 20070301 |
| In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. | Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 20040701 |
| The activity of grepafloxacin in two murine models of Mycobacterium avium infection. | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 20040601 |
| New agents active against Mycobacterium avium complex selected by molecular topology: a virtual screening method. | The Journal of antimicrobial chemotherapy 20040101 |
| Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. | Antimicrobial agents and chemotherapy 20030101 |
| In vitro effect of short-term exposure to two synthetic peptides, alone or in combination with clarithromycin or rifabutin, on Cryptosporidium parvum infectivity. | Peptides 20020501 |
| CYP3A inductive potential of the rifamycins, rifabutin and rifampin, in the rabbit. | Biopharmaceutics & drug disposition 20010501 |
| Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. | Antimicrobial agents and chemotherapy 20010101 |
| Activity of rifapentine and its metabolite 25-O-desacetylrifapentine compared with rifampicin and rifabutin against Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis and M. bovis BCG. | The Journal of antimicrobial chemotherapy 20001001 |
| Therapeutic efficacy of liposomal rifabutin in a Mycobacterium avium model of infection. | Antimicrobial agents and chemotherapy 20000901 |
| Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. | The Journal of antimicrobial chemotherapy 20000401 |
| Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs. | Biochemical pharmacology 20000201 |
| In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. | The Journal of antimicrobial chemotherapy 19991101 |
| In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19991101 |
| Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis. | Journal of clinical microbiology 19990201 |
| Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice. | Microbial drug resistance (Larchmont, N.Y.) 19990101 |
| Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. | The Journal of antimicrobial chemotherapy 19981101 |
| In vitro activity of antimicrobial combinations against clinical isolates of susceptible and resistant Mycobacterium tuberculosis. | The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 19980801 |
| Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. | Antimicrobial agents and chemotherapy 19980701 |
| [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model]. | Kekkaku : [Tuberculosis] 19980201 |
| Rapid drug susceptibility of Mycobacterium avium complex using a fluorescence quenching method. | Journal of chemotherapy (Florence, Italy) 19970801 |
| Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. | Antimicrobial agents and chemotherapy 19970501 |
| Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. | Clinical pharmacology and therapeutics 19970501 |
| Clinically used antimicrobial drugs against experimental pneumocystosis, singly and in combination: analysis of drug interactions and efficacies. | Antimicrobial agents and chemotherapy 19970201 |
| Low-dose aerosol infection model for testing drugs for efficacy against Mycobacterium tuberculosis. | Antimicrobial agents and chemotherapy 19961201 |
| In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. | Antimicrobial agents and chemotherapy 19960901 |
| Comparative activity of azithromycin against clinical isolates of mycobacteria. | The Journal of antimicrobial chemotherapy 19960901 |
| Susceptibility testing of Mycobacterium avium complex isolates. | Antimicrobial agents and chemotherapy 19960801 |
| Rifapentine is active in vitro and in vivo against Toxoplasma gondii. | Antimicrobial agents and chemotherapy 19960601 |
| Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice. | European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19960501 |
| Chemotherapeutic activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium tuberculosis in C57BL/6 mice. | Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 19960401 |
| Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages. | The Journal of antimicrobial chemotherapy 19960301 |
| How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice? | Antimicrobial agents and chemotherapy 19960201 |
| Rifamycin resistance in mycobacteria. | Research in microbiology 19960101 |
| Evaluation of the activities of rifabutin combined with atovaquone or low-dose of cotrimoxazole for prevention of pneumocystosis and toxoplasmosis in a dual infection rat model. | The Journal of eukaryotic microbiology 19960101 |
| In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. | Antimicrobial agents and chemotherapy 19951001 |
| New drugs for tuberculosis. | The European respiratory journal. Supplement 19950901 |
| Activity of seven antimicrobial agents, alone and in combination, against AIDS-associated isolates of Mycobacterium avium complex. | The Journal of antimicrobial chemotherapy 19950901 |
| In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli. | The Journal of antimicrobial chemotherapy 19950801 |
| [Extra and intracellular activity of dirithromycin against Mycobacterium avium]. | Pathologie-biologie 19950401 |
| Comparison of activities of fluoroquinolones in murine macrophages infected with Mycobacterium tuberculosis. | Antimicrobial agents and chemotherapy 19950301 |
| Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. | Antimicrobial agents and chemotherapy 19950301 |
| Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. | The Journal of antimicrobial chemotherapy 19950201 |
| Clinical experience with rifabutin in the treatment of mycobacterial infections. | Scandinavian journal of infectious diseases. Supplementum 19950101 |
| [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. | Kekkaku : [Tuberculosis] 19941101 |
| Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. | Antimicrobial agents and chemotherapy 19941101 |
| A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions. | Antimicrobial agents and chemotherapy 19941101 |
| Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. | Antimicrobial agents and chemotherapy 19941001 |
| In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi. | Antimicrobial agents and chemotherapy 19941001 |
| Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. | Drugs 19940601 |
| In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivatives. | Antimicrobial agents and chemotherapy 19940501 |
| Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells. | Antimicrobial agents and chemotherapy 19940501 |
| Rifabutin is active in murine models of toxoplasmosis. | Antimicrobial agents and chemotherapy 19940301 |
| Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex. | Antimicrobial agents and chemotherapy 19940201 |
| Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice. | The American review of respiratory disease 19931201 |
| Anti-Mycobacterium avium activity of quinolones: in vitro activities. | Antimicrobial agents and chemotherapy 19930901 |
| Azithromycin, rifabutin, and rifapentine for treatment and prophylaxis of Mycobacterium avium complex in rats treated with cyclosporine. | Antimicrobial agents and chemotherapy 19930301 |
| In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. | Antimicrobial agents and chemotherapy 19930101 |
| Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. | Chemical & pharmaceutical bulletin 19930101 |
| Spectrum of drugs against atypical mycobacteria: how valid is the current practice of drug susceptibility testing and the choice of drugs? | Zentralblatt fur Bakteriologie : international journal of medical microbiology 19921201 |
| Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | Antimicrobial agents and chemotherapy 19920901 |
| Activity of azithromycin against Mycobacterium avium infection in beige mice. | Antimicrobial agents and chemotherapy 19920801 |
| Chlorpromazine: a drug potentially useful for treating mycobacterial infections. | Chemotherapy 19920101 |
| Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. | The American review of respiratory disease 19920101 |
| In vivo activities of newer rifamycin analogs against Mycobacterium avium infection. | Antimicrobial agents and chemotherapy 19911001 |
| [Activity of antibiotics against pigmented and unpigmented variants of Mycobacterium avium-intracellulare]. | Pathologie-biologie 19910501 |
| In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. | Antimicrobial agents and chemotherapy 19910301 |
| Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. | Diagnostic microbiology and infectious disease 19910101 |
| [In vivo activities of new rifamycin derivatives against mycobacteria]. | Kekkaku : [Tuberculosis] 19910101 |
| [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex]. | Kekkaku : [Tuberculosis] 19901201 |
| Effect of rifabutin on disseminated Mycobacterium avium infections in thymectomized, CD4 T-cell-deficient mice. | Antimicrobial agents and chemotherapy 19900901 |
| Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. | Antimicrobial agents and chemotherapy 19900801 |
| In vitro activities against mycobacteria of two long-acting rifamycins, FCE22807 and CGP40/469A (SPA-S-565). | Tubercle 19900601 |
| [Activity of azithromycin and roxithromycin alone or in combination against Mycobacterium avium and Mycobacterium xenopi]. | Pathologie-biologie 19900501 |
| Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. | The American review of respiratory disease 19900301 |
| Comparative in-vitro activity of fleroxacin and other 6-fluoroquinolones against mycobacteria. | The Journal of antimicrobial chemotherapy 19881001 |
| In vitro effectiveness of a combination of zidovudine and ansamycin against human immunodeficiency virus. | The Journal of infectious diseases 19881001 |
| Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. | Tubercle 19880901 |
| New antibacterial drugs for the treatment of mycobacterial disease in man. | British medical bulletin 19880701 |
| Interaction between rifabutin and human immunodeficiency virus type 1: inhibition of replication, cytopathic effect, and reverse transcriptase in vitro. | Antimicrobial agents and chemotherapy 19880501 |
| Qualitative and quantitative drug-susceptibility tests in mycobacteriology. | The American review of respiratory disease 19880501 |
| Combinations of rifampin or rifabutine plus ethambutol against Mycobacterium avium complex. Bactericidal synergistic, and bacteriostatic additive or synergistic effects. | The American review of respiratory disease 19880301 |
| Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis. | The American review of respiratory disease 19880301 |
| In vitro activity of antimicrobial agents against mycobacteria. | Drugs under experimental and clinical research 19880101 |
| Action of antituberculous and beta-lactam drugs (including imipenem) against extra- and intra-cellularly growing Mycobacterium avium-intracellulare. | Annales de l'Institut Pasteur. Microbiology 19880101 |
| In vitro susceptibility of Mycobacterium avium complex to antibacterial agents. | Diagnostic microbiology and infectious disease 19871101 |
| In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. | Tubercle 19870901 |
| Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. | The American review of respiratory disease 19870801 |
| Determination of MICs of conventional and experimental drugs in liquid medium by the radiometric method against Mycobacterium avium complex. | Drugs under experimental and clinical research 19870101 |
| Rifabutine inhibits HTLV-III. | Lancet (London, England) 19860111 |
| Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods. | Antimicrobial agents and chemotherapy 19851001 |
| Determination of in vitro susceptibility of mycobacteria to ansamycin. | The American review of respiratory disease 19850901 |
| Comparative in vitro activities of MDL 473, rifampin, and ansamycin against Mycobacterium intracellulare. | Antimicrobial agents and chemotherapy 19850901 |
| Activity of the spiropiperidyl rifamycin LM 427 on rifampicin resistant Mycobacterium tuberculosis. | Giornale italiano di chemioterapia 19840101 |
| LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies. | The Journal of antibiotics 19831101 |
| In vitro susceptibility of Mycobacterium avium complex and Mycobacterium tuberculosis strains to a spiro-piperidyl rifamycin. | The American review of respiratory disease 19820901 |
| Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins. | The Journal of antibiotics 19801001 |
Related Products
© 2019 Angene International Limited. All rights Reserved.